Fresenius Medical (FMS) Well Poised on Growth Strategy 2020

On Oct 9, we issued an updated research report on Bad Homburg, Germany-based Fresenius Medical Care FMS, one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure.

Fresenius Medical has chalked out a long-term plan called the ‘Growth Strategy 2020’ to formulate a few initiatives for gaining solid market traction over the long haul.

Per the postulates of Growth Strategy 2020, Fresenius Medical aims to increase revenues to $28 billion by 2020, reflecting an average annual growth rate of around 10%. In full-year 2016, revenues increased 7% on a year-over-year basis, courtesy of strong growth in Health Care Service revenues. Furthermore, management forecasts an increase in revenues through both organic and inorganic growth.

In addition to the stock’s strong performance in its core dialysis business, Fresenius Medical intends to achieve targets by expanding its Care Coordination (non-dialysis segment) as well.

Coming to product lines, Fresenius Medical manufactures a variety of durable medical devices used in the treatment of End Stage Renal Disease (ESRD). Devices like Hemodialysis Machines, Peritoneal Dialysis Machines, Granuflo Concentrate Mixing Tanks and monitoring devices like the Crit-line platform are part of its portfolio.

Fresenius Medical provides a wide range of dialysis products in its clinics and to third parties. These include modular machine components, dialyzers, bloodline systems, HD (hemodialysis) solutions, concentrates and water treatment systems.

Acquisitions have been driving the company’s growth trajectory for long. Among the major ones, the buyouts of Cura Group, XENiOS AG, Renal Care Group, Renal Solutions, Liberty Dialysis and Sparsh Nephrocare deserve a special mention. In 2016, the company made acquisitions worth $367 million.

On the flipside, Fresenius Medical has had an unimpressive run on the bourse year to date. The stock has gained 14.4%, lower than the industry’s addition of almost 19.9%.

 

 

Zacks Rank & Key Picks

Fresenius Medical currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the medical sector are Orthofix International N.V. OFIX, Luminex Corporation LMNX and IDEXX Laboratories, Inc IDXX. Orthofix International and Luminex Corporation sport a Zacks Rank #1 (Strong Buy), while IDEXX Laboratories carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Orthofix International has a long-term expected earnings growth rate of 11.8%. The stock has surged roughly 39.1% over the last six months.

Luminex Corporation has a long-term expected earnings growth rate of 16.3%. The stock has rallied 14.1% over the last six months.

IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has climbed 39.2% over a year’s time.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Luminex Corporation (LMNX) : Free Stock Analysis Report
 
Fresenius Medical Care Corporation (FMS) : Free Stock Analysis Report
 
IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report
 
Orthofix International N.V. (OFIX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.